A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma \[cutaneous/acral\], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric cancer ovarian carcinoma, cervical cancer, endometrial cancer, bladder cancer, esophageal carcinoma, pancreatic carcinoma, prostate cancer, second-line gastric cancer, lung cancer, and breast cancer.

Trial Details

NCT ID
NCT06172478
Phase
PHASE2
Sponsor
Daiichi Sankyo
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • HER3-DXd
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • New Haven, Connecticut, United States|41.30815,-72.92816
  • Kissimmee, Florida, United States|28.30468,-81.41667
  • Chicago, Illinois, United States|41.85003,-87.65005
  • Baltimore, Maryland, United States|39.29038,-76.61219

Key Eligibility Criteria

  • Participants must meet all of the following criteria to be eligible for enrollment into the study:
  • Sign and date the informed consent form prior to the start of any study-specific qualification procedures. A separate tissue screening consent will…
  • Participants aged ≥18 years (follow local regulatory requirements if the legal age of consent for study participation is \>18 years old).
  • Has locally advanced unresectable or metastatic disease (not curable by surgery or radiation) as follows:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →